Gene Xpert MTB/RIF Assay as A New Tool for Tuberculosis Diagnosis and Detection of Rifampin Resistance
Al Olimey, R., AbdElSamie, S., Kamel, M., Khamis, A. (2019). Gene Xpert MTB/RIF Assay as A New Tool for Tuberculosis Diagnosis and Detection of Rifampin Resistance. EKB Journal Management System, 22(2), 179-186. doi: 10.21608/scumj.2019.110680
Rabab Al Olimey; Sohier AbdElSamie; Mohamed Kamel; Afaf Khamis. "Gene Xpert MTB/RIF Assay as A New Tool for Tuberculosis Diagnosis and Detection of Rifampin Resistance". EKB Journal Management System, 22, 2, 2019, 179-186. doi: 10.21608/scumj.2019.110680
Al Olimey, R., AbdElSamie, S., Kamel, M., Khamis, A. (2019). 'Gene Xpert MTB/RIF Assay as A New Tool for Tuberculosis Diagnosis and Detection of Rifampin Resistance', EKB Journal Management System, 22(2), pp. 179-186. doi: 10.21608/scumj.2019.110680
Al Olimey, R., AbdElSamie, S., Kamel, M., Khamis, A. Gene Xpert MTB/RIF Assay as A New Tool for Tuberculosis Diagnosis and Detection of Rifampin Resistance. EKB Journal Management System, 2019; 22(2): 179-186. doi: 10.21608/scumj.2019.110680

Gene Xpert MTB/RIF Assay as A New Tool for Tuberculosis Diagnosis and Detection of Rifampin Resistance

Suez Canal University Medical Journal
Article 10, Volume 22, Issue 2, October 2019, Page 179-186  XML PDF (262.76 K)
Document Type: Original Article
DOI: 10.21608/scumj.2019.110680
View on SCiNiTO View on SCiNiTO
Authors
Rabab Al Olimey email 1; Sohier AbdElSamie1; Mohamed Kamel2; Afaf Khamis1
1Department of Chemical and Clinical Pathology, Faculty of Medicine, Benha University, Egypt
2Department of Internal Medicine (Chest), Faculty of Medicine, Benha University, Egypt
Abstract
Background: Mycobacterium tuberculosis (MTB) is one of the top ten causes of death and the leading cause of a single infectious agent (above HIV/AIDS) Worldwide. Each year millions of people continue to fall sick with TB. Aim: To evaluate the MTB/RIF assay for rapid diagnosis and detection of rifampin resistance of tuberculosis in both positive and negative smears-as well as pulmonary and non-pulmonary clinical specimens. Patients and Methods: A prospective study was conducted on 50 patients (37 pulmonary, 13 extrapulmonary) patients attending the Outpatient Clinic and inpatients of Chest Department, Benha University Hospital, Egypt. Pulmonary samples were analyzed by (Sputum smear exam. by Ziehl Neelsen (ZN) stain, culture on Lowenstein-Jensen(LJ)media, and assessment of rifampin sensitivity). Extrapulmonary samples were analyzed by reference methods (pathological diagnosis) and by GeneXpert. Results: pulmonary patients’ smears were 32 (86.5%) positive and 5 (13.5%) negative. Culture on LJrevealed rifampin sensitivity in 33/37 (89.1%) and rifampin-resistant in 4/37 (10.9%), GeneXpert was positive in 32(86.5%) and negative in 5 (13.5%), rifampin assay was sensitive in 33 (89.1%) and resistant in 4(10.9%). All extrapulmonary patients, (n=13) were positive on GeneXpert and sensitive for rifampin. Conclusion: GeneXpert could be considered as a leading way to early diagnosis, treatment, and prevention of transmission of tuberculosis which could reduce TB- associated morbidity and mortality.
Keywords
Ziehl-Neelsen Smears; Lowenstein-Jensen media; and Rifampin sensitivity
Statistics
Article View: 213
PDF Download: 682